115. Post-licensure Safety Study of New-onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis in Adult Recipients of HepB-CPG Vaccine Versus HepB-alum Vaccine

BACKGROUND: HepB-CpG (Heplisav-B; Dynavax) is a licensed hepatitis B vaccine with a novel adjuvant that requires only 2 doses (0, 1 month) compared to a 3-dose (0, 1, 6 months) HepB-alum vaccine (Engerix-B; GlaxoSmithKline). Monitoring of safety outcomes following receipt of vaccines with novel adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Ackerson, Bradley, Sy, Lina S, Slezak, Jeff, Qian, Lei, Reynolds, Kristi, Huang, Runxin, Solano, Zendi, Towner, William, Qiu, Sijia, Simmons, Sarah, Jacobsen, Steven, Bruxvoort, Katia J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752391/
http://dx.doi.org/10.1093/ofid/ofac492.193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752391/
http://dx.doi.org/10.1093/ofid/ofac492.193

Ejemplares similares